Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness by reducing cutaneous dose-limiting toxicity. Its lead asset, LUT014, is a topical B‑Raf inhibitor designed to treat EGFR inhibitor–induced acneiform rash and potentially allow patients to continue EGFRi therapy. LUT014 completed enrollment in an international phase 2 trial in metastatic colorectal cancer patients in October 2024, and the company expects to report top-line results in the first half of 2025 at a major medical meeting. Lutris also successfully completed a phase 1/2 study of LUT014 for radiation-induced dermatitis in breast cancer patients. The company aims to provide novel topical therapies to mitigate dermal side effects, improve quality of life, and enable adherence to anti-cancer regimens. Lutris Pharma is based in Tel Aviv, Israel. The company recently secured financing to advance the clinical development of LUT014.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2025